Xenetic Biosciences, Inc. is a biopharmaceutical company based in Framingham, MA, dedicated to advancing innovative immune-oncology technologies. With a focus on proprietary technology platforms, they aim to target neutrophil extracellular traps (NETs), which are known to drive cancer progression and metastasis, as well as contribute to resistance to chemotherapy, checkpoint inhibitors, and radiotherapy.
Through their DNase I Oncology Platform, Xenetic Biosciences is actively working towards improving cancer therapies and addressing multiple high-value cancer indications, including pancreatic cancer and other solid tumors. With a commitment to advancing research and development, they have entered into a research agreement with the University of Virginia to further advance their DNase-based oncology platform.
Generated from the website